Korro Bio, Inc.
corporate_fare Company Profile
Korro Bio, Inc. (NASDAQ:KRRO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for KRRO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for KRRO spans 8-K, 4, 10-Q, 144.
Recent high-impact activity:
- Novo Nordisk Ends $530M RNA-Editing Pact; Korro Bio Falls 11%
- Novo Nordisk Terminates Korro Bio Collaboration, Effective February 2027
- 10% Owner Lynx1 Buys $885K of Korro Bio Stock in Four Open-Market Trades
- Korro Bio Reports Preclinical KRRO-111 Data Showing Up to 95% Liver Z-AAT Reduction in AATD
- Korro's KRRO-111 Edits SERPINA1 Up to 96% in Preclinical AATD Data, Filing Set for 1H 2027
Financial Snapshot
Short Interest & Short Volume
8.18 days to coverFINRA reported short interest of 1,749,169 shares in KRRO as of the October 30, 2026 settlement, a 0.9% increase from the prior period — about 8.2 days to cover at its recent average daily volume. On November 20, 2026, 71.1% of KRRO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.